FDA approve Keytruda as adjuvant treatment for kidney cancer

The FDA has approved Keytruda® for the treatment of patients with early renal cell carcinoma at high or intermediate-high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. Keytruda is typically used to treat advanced types of cancers such as lung cancer and melanoma, by working with a patient’s immune system. The PD-1 inhibitor is the first immunotherapy to enter the field.

read more